T Cell News and Research

Latest T Cell News and Research

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.

21 Aug 2009

Clinical grade stem cells to be manufactured by Stemedica as it awaits FDA approval of an IND to commence clinical trials

Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

21 Aug 2009

Cannabis chemicals stop prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

21 Aug 2009

Care Support Of America CEO offers advice on caregiving to aging relatives

Summer has its own serious issues for seniors living at home, but a little bit of planning by family caregivers can go a long way should a weather emergency occur. Summer emergencies include not only major disasters like hurricanes and wildfires, but also heat emergencies and storms that knock out electricity and access to services," says Dr. Dan Tobin, CEO of Care Support of America, a national family caregiving service.

21 Aug 2009

Ends of protein templates useful for arresting growth of cancerous cells

The tail ends of cellular protein templates, regions often thought relatively inconsequential, may actually play a role in preventing normal cells from becoming cancerous. The finding from scientists at Whitehead Institute for Biomedical research is reported in the August 20 edition of Cell.

21 Aug 2009

Nixle's free technology provides critical real-time alerts on H1N1 Flu

Nixle, a secure community information tool, which has been rapidly adopted by over 1,800 law enforcement agencies across the country, is now offering its free technology to hospitals and schools to provide critical real-time alerts on the H1N1 Flu.

21 Aug 2009

Research study discovers lethal effects of tetracycline and chloramphenicol against certain bacterial strains

By studying the intricate mechanisms at work in protein production, a Princeton-led team has discovered why certain kinds of antibiotics are so effective. In doing so, they also have discovered how one protein protects against cell death, shedding light on a natural cancer-fighting process.

21 Aug 2009

Researchers develop new ways for splitting dangerous pair of cancer proteins

A research team led by U of T Mississauga scientists has developed a new way to split up a dangerous pair of cancer proteins, a finding that could ultimately lead to chemotherapy that is more effective and has fewer side effects.

21 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

More evidence that genes increase a smokers' risk of lung cancer

Cancer Research UK funded scientists have confirmed that inherited changes in certain regions of the genome can increase a smokers' risk of developing lung cancer lung cancer, and determine the type of lung cancer that develops. Their results were published in this week's edition of the journal Cancer Research*.

21 Aug 2009

New discovery on cellular fusion

Success in soccer sometimes comes with "bending it like Beckham." Success in cellular fusion - as occurs at the moment of conception and when nerve cells exchange neurotransmitters - requires that a membrane be bent before the merging process can begin, University of Wisconsin-Madison researchers have shown.

20 Aug 2009

IBISS research group's project aims to examine Ribavirin role in promoting the survival of transplanted stem cells

Hard to Treat Diseases (HTDS.PK) Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats.

20 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Shape-changing in proteins opens new avenue for drug discovery

Computational biologists at the University of Pittsburgh School of Medicine have shown that proteins have an intrinsic ability to change shape, and this is required for their biological activity. This shape-changing also allows the small molecules that are attracted to a given protein to select the structure that permits the best binding. That premise could help in drug discovery and in designing compounds that will have the most impact on protein function to better treat a host of diseases.

20 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Mesenchymal stem cells repair human brain

There is no known cure for neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's. But new hope, in the form of stem cells created from the patient's own bone marrow, can be found ― and literally seen ― in laboratories at Tel Aviv University.

20 Aug 2009

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

A new blood test, measuring the level of omega-3 fatty acids in red blood cells, is now broadly available for the first time to the public everywhere as a consumer-friendly, at-home "finger stick" test. While scientists have long known of the benefits of fish and fish oil for overall heart health, over the past decade research has proven that the omega-3 fatty acids found in fish dramatically reduce one's risk for cardiovascular disease. Further, recent research indicates that omega-3 levels may be among the best predictors of future coronary heart disease - providing much stronger correlations to the risk of sudden cardiac death than traditional indicators, including HDL and LDL cholesterol.

20 Aug 2009

Novel microRNA plays a major role in invasive breast cancer development

Research led by Suresh Alahari, PhD, Associate Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, has shown for the first time that a tiny piece of RNA appears to play a major role in the development of invasive breast cancer and identified a gene that appears to inhibit invasive breast cancer.

20 Aug 2009

Peplin completes four-week enrolment phase for REGION-Ib trial

Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.

20 Aug 2009